At SICEM 2026, we are honored to welcome William F. Young, Jr. of Mayo Clinic as the sole honorary keynote speaker. Prof. Young has built an outstanding body of research elucidating the pathophysiology of secondary hypertension caused by adrenal and pituitary disorders and is widely recognized as a global authority in the fields of primary aldosteronism and pheochromocytoma. He has also played a leading role in the development of international clinical practice guidelines that have established the diagnostic and therapeutic standards for these conditions. In this honorary keynote lecture, entitled “Primary aldosteronism: A guideline-driven case-based approach,” Prof. Young will present a systematic and practical overview of diagnostic strategies, subtyping, and treatment approaches, applying the latest guidelines to real-world clinical cases.

Prof. Ian R. Reid has been actively involved in research since the early development of bisphosphonate therapeutics and is a leading authority in the fields of calcium metabolism, osteoporosis, and Paget's disease. Notably, he has made a significant impact on this field by publishing the results of a clinical study applying zoledronate to osteopenia.
As sequential therapy is increasingly emphasized as essential in current osteoporosis management, the critical role of bisphosphonates, and zoledronate in particular, is gaining renewed importance.
In this Plenary lecture, Prof. Ian R. Reid will provide profound insights into the role of zoledronate in osteoporosis treatment and the new direction for osteoporosis therapy expected to be established in 2026.

Type 2 diabetes extends beyond a simple metabolic disorder, intricately linked to the disruption of circadian rhythmicity. Prof. Juleen R. Zierath's pioneering research has identified the loss of rhythmic expression of clock genes, including BMAL1 and CLOCK, in skeletal muscle of diabetic patients as a critical molecular nexus connecting mitochondrial dysfunction and insulin resistance. Her recent work has elucidated the mechanisms by which exercise resets tissue-specific metabolic rhythms and the complexity of time-dependent metabolic responses. Notably, her 2025 study characterizing individual molecular signatures of insulin resistance provides crucial insights toward precision medicine approaches in metabolic diseases. In this plenary lecture, Prof. Zierath will present cutting-edge findings on how circadian disruption contributes to type 2 diabetes pathogenesis and discuss therapeutic implications of targeting metabolic rhythmicity for improved clinical outcomes.

Approaches that re-differentiate thyroid cells to enhance RAI uptake or retention to improve RAI treatment outcomes have long been an area of research and clinical interest. While early attempts with agents like retinoic acid and lithium yielded limited success, recent clinical trials targeting the MAPK pathway have shown promising results in BRAF- and RAS-mutated DTC.
Prof. Sophie Leboulleux from the University of Geneva is a global leader in this field. She has led landmark prospective trials, including a phase II trial evaluating the efficacy and safety of dabrafenib and trametinib combined with 131I for RAI-refractory DTC. In this plenary lecture, she will provide profound insights into the current landscape and future directions of redifferentiation therapy.